MX2018010367A - Titulacion de cebranopadol. - Google Patents
Titulacion de cebranopadol.Info
- Publication number
- MX2018010367A MX2018010367A MX2018010367A MX2018010367A MX2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A
- Authority
- MX
- Mexico
- Prior art keywords
- cebranopadol
- daily dose
- administration interval
- administered
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere a Cebranopadol para su uso en el tratamiento de dolor, donde Cebranopadol se administra de acuerdo con un régimen de administración que comprende (i) un primer intervalo de administración, que dura al menos 2 días consecutivos, donde una primera dosis diaria de Cebranopadol se administra todos los días del primer intervalo de administración; y (ii) un segundo intervalo de administración, que dura al menos 2 días consecutivos y que le sigue directamente al primer intervalo de administración sin interrupción, donde una segunda dosis diaria de Cebranopadol se administra todos los días del segundo intervalo de administración; donde la primera dosis diaria de Cebranopadol es menor que la segunda dosis diaria de Cebranopadol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16157868 | 2016-02-29 | ||
EP16020302 | 2016-08-11 | ||
PCT/EP2017/025034 WO2017148595A1 (en) | 2016-02-29 | 2017-02-28 | Titration of cebranopadol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010367A true MX2018010367A (es) | 2018-12-10 |
Family
ID=58185482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018010367A MX2018010367A (es) | 2016-02-29 | 2017-02-28 | Titulacion de cebranopadol. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11229625B2 (es) |
EP (1) | EP3423054A1 (es) |
JP (2) | JP7373904B2 (es) |
CN (2) | CN109069483A (es) |
AU (1) | AU2017226830B2 (es) |
BR (1) | BR112018017167A2 (es) |
CA (1) | CA3015420C (es) |
IL (1) | IL261133A (es) |
MX (1) | MX2018010367A (es) |
WO (1) | WO2017148595A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1126834A1 (en) * | 1998-11-02 | 2001-08-29 | Ortho-McNeil Pharmaceutical, Inc. | Analgesic regimen |
US6339105B1 (en) * | 1999-10-12 | 2002-01-15 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
WO2004054553A1 (en) * | 2002-12-13 | 2004-07-01 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for analgesia |
US7413749B2 (en) * | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
HUE028436T2 (hu) | 2010-08-04 | 2016-12-28 | Gruenenthal Gmbh | Gyógyszerészeti adagolási forma, amely tartalmaz-6'-fluor-(N-metil- vagy N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-spiro[ciklohexán-1,1'-pirano[3,4B]indol]-4-amint |
PL2600838T3 (pl) | 2010-08-04 | 2016-02-29 | Gruenenthal Gmbh | Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(N-metylo- lub N,N-dimetylo)-4-fenylo-4'9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4b]indolo]-4-aminę |
TR201808244T4 (tr) * | 2010-08-04 | 2018-07-23 | Gruenenthal Gmbh | Nöropatik ağrının tedavisi için 6'-floro-(n-metil- veya n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[siklohekzan-1,1'-pirano[3,4,b]indol]-4-amin içeren farmasötik dozaj formu. |
AU2011287956B2 (en) | 2010-08-04 | 2015-01-22 | Grunenthal Gmbh | Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4,9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
LT2729470T (lt) | 2011-07-08 | 2017-08-25 | Grünenthal GmbH | Kristalinis (1r,4r)-6`-fluor-n,n-dimetil-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-aminas |
-
2017
- 2017-02-28 MX MX2018010367A patent/MX2018010367A/es unknown
- 2017-02-28 CN CN201780013921.3A patent/CN109069483A/zh active Pending
- 2017-02-28 CN CN202410387184.5A patent/CN118286209A/zh active Pending
- 2017-02-28 JP JP2018543634A patent/JP7373904B2/ja active Active
- 2017-02-28 AU AU2017226830A patent/AU2017226830B2/en not_active Expired - Fee Related
- 2017-02-28 CA CA3015420A patent/CA3015420C/en active Active
- 2017-02-28 EP EP17707471.3A patent/EP3423054A1/en active Pending
- 2017-02-28 WO PCT/EP2017/025034 patent/WO2017148595A1/en active Application Filing
- 2017-02-28 BR BR112018017167A patent/BR112018017167A2/pt not_active IP Right Cessation
-
2018
- 2018-08-13 IL IL261133A patent/IL261133A/en unknown
- 2018-08-29 US US16/116,055 patent/US11229625B2/en active Active
-
2021
- 2021-07-05 JP JP2021111672A patent/JP2021169472A/ja active Pending
- 2021-12-21 US US17/557,987 patent/US20220110914A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017226830B2 (en) | 2021-06-24 |
CA3015420A1 (en) | 2017-09-08 |
CA3015420C (en) | 2023-09-26 |
US11229625B2 (en) | 2022-01-25 |
JP7373904B2 (ja) | 2023-11-06 |
US20180369199A1 (en) | 2018-12-27 |
IL261133A (en) | 2018-10-31 |
AU2017226830A1 (en) | 2018-08-16 |
CN118286209A (zh) | 2024-07-05 |
JP2021169472A (ja) | 2021-10-28 |
BR112018017167A2 (pt) | 2019-01-02 |
US20220110914A1 (en) | 2022-04-14 |
JP2019507148A (ja) | 2019-03-14 |
WO2017148595A1 (en) | 2017-09-08 |
EP3423054A1 (en) | 2019-01-09 |
CN109069483A (zh) | 2018-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018234568A3 (en) | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION | |
PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
NZ751137A (en) | System, device and methods of seed treatment | |
EA201890507A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
MX2020011817A (es) | Metodos para tratar el linfoma. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
JOP20220092A1 (ar) | جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر | |
MX2022000143A (es) | Metodos novedosos. | |
MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
MX2018010367A (es) | Titulacion de cebranopadol. | |
MX2020013385A (es) | Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion. | |
MX2020010938A (es) | Medicamento para prevenir y/o tratar el dolor y/o la fiebre, producto compuesto y uso del mismo. | |
PH12017501918A1 (en) | Multi-peptide composition | |
MX2021004511A (es) | Medicamento para el tratamiento y/o mejora de la septicemia asociada con la anomalia de la coagulacion. | |
MX2023005681A (es) | Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol. | |
UA117853U (uk) | Спосіб лікування гострої респіраторної вірусної інфекції у дітей | |
EA202190033A1 (ru) | Соединения пиразола и имидазола для ингибирования il-17 и ror-гамма |